Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Terminated 2Withdrawn 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Neurodegenerative Diseases 1Ischemic Stroke 1Hemorrhagic Stroke 1Central Nervous System Vascular Malformations 1Central Nervous System Infections 1Brain Neoplasms 1Brain Injuries 1

Interventions

Cyclophosphamide 1495Cisplatin 1431Paclitaxel 1339Radiotherapy 1308Carboplatin 1264Gemcitabine 1225Docetaxel 1134Bevacizumab 1068Fluorouracil 906Doxorubicin 799Dexamethasone 753Rituximab 744Capecitabine 735Oxaliplatin 709pembrolizumab 693Etoposide 674Irinotecan 639Filgrastim 624Nivolumab 585Cytarabine 585Leucovorin 582Vincristine 512Cetuximab 478Prednisone 477Bortezomib 472Trastuzumab 469Erlotinib Hydrochloride 467Surveys and Questionnaires 460Methotrexate 443Lenalidomide 434

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Tissue Array Analysis × Clear all
NCT02452216 2017-08-31

Using Ferumoxytol-Enhanced MRI to Measure Inflammation in Patients With Brain Tumors or Other Conditions of the CNS

Stanford University

Phase EARLY_PHASE1 Completed
10 enrolled
CNS

Ischemic Stroke, Hemorrhagic Stroke, Brain Injuries, Brain Neoplasms, Central Nervous System Infections, Neurodegenerative Diseases, Central Nervous System Vascular Malformations

Data powered by HemOnc (CC BY 4.0) Colophon âš¡